38 million shares become available for sale Monday- that's far more than the 23 million shares sold in the IPO.
Currently at + $5.61 over the IPO price of $20, profit taking likely to ensue- especially since Go Daddy's losses are widening and is deeply in debt in a low threshold business.
ILMN is the runaway leader in sequencing. PACB is a niche player, to date selling mostly to research institutions, a narrow market.
PACB sells only about a dozen machines a year.
PACB latest iteration still is MUCH more expensive than ILMN.
PACB will have to dilute with more shares when the last small payment from Roche comes in this quarter
PACB is a highly manipulated stock, so much so Jim Cramer warned in the past not to chase it.
On the contrary, sequencing- while noble work, is far from lucrative. PacBio (PACB) is consistently unprofitable.
Their just announced ititeration is still too expensive- uncompetitive in the marketplace.
Company has just gone dark on reporting machines sold- not a good sign.
This a low PPS play for "players" and will end badly- always does.
Bloomberg Article part 3.
Valeant also said, on the Oct. 26 call, that sales hadn’t been artificially inflated because it consolidates Philidor’s results on its own books and doesn’t record those sales until prescriptions are shipped to patients.
It said it didn’t have to declare its interest in Philidor because the specialty pharmacy network has accounted for about 6 percent of Valeant revenue so far this year. That is below the 10 percent sales threshold that would make the arrangement material under Generally Accepted Accounting Principles, the company said in its presentation.
Valeant declined to provide additional comment. It has called R&O’s payment-dispute lawsuit “without merit” and said it will file a counterclaim.
Philidor referred requests for comment to public-relations firm Hill & Knowlton, which declined to comment, citing pending lawsuits. Lawyers for Isolani didn’t respond to requests for comment.
Isolani alleged in its California suit that Reitz and his pharmacy were withholding drug reimbursements that weren’t theirs, and that Reitz had breached his contractual obligations while Isolani had upheld theirs. Philidor, which is mentioned in e-mails and documents filed as part of that suit, isn’t a party.
Reitz’s lawyer, Gary Jay Kaufman, declined to comment via e-mail.
The Tiny Pharmacy at the Center of Valeant's Money Mystery
October 29, 2015 — 5:00 AM EDT
After agreeing to sell his pharmacy, owner's questions mounted
Long before investors directed a barrage of scrutiny at Valeant Pharmaceuticals International Inc., one Southern California pharmacist began pulling on a thread.
Valeant disclosed last week that it had ties to a network of pharmacies filling prescriptions for its drugs across the U.S., setting off a $10 billion drop in its market value as investors struggled to reassess the company’s sales picture. Asked why it hadn’t talked sooner about the related web of pharmacies, Valeant said that it hadn’t been bound to do so.
But the company has had little option but to explain itself in the past week thanks to a growing chorus of questions -- among the first of which came from R&O Pharmacy, a smoked-glass storefront amid rows of low-slung office buildings in Camarillo, California.
Less than a year ago, 64-year-old pharmacist Russell Reitz agreed to sell his business there to a Delaware-registered company for $350,000. R&O soon became the victim of widespread fraud, Reitz’s lawyer alleged in documents filed in a billing suit against him in state court in California.
Even before the sale agreement was executed, other pharmacies began using an R&O identification number to bill for prescriptions that R&O hadn’t filled, sometimes for drugs the store...
Illumina is catching most of the profit that's out there. PacBio and the dozens of sequencing companies are no Illumina.
Saying Roche is "desperately.." is hype.
This is a low PPS play that "players" jump on every PR. If you have any insight, you know that.
Thomson Reuters/Verus upgrades SYSOREX GLOBAL HOLDINGS CORPORATION from HOLD to BUY.
BY Investars Analyst Actions - public— 11:05 AM ET 10/05/2015
On October 5, 2015 Thomson Reuters/Verus upgraded SYSOREX GLOBAL HOLDINGS CORPORATION (SYRX) from HOLD to BUY.
No, still not a overly lucrative field- yet. Guessing about 1.5B divided by MANY.
Best can be said is it is growing. But we're talking about NOW. A PPS up 68% on a modest PR from a company consistently losing money and widening is beyond a natural reaction- it's a low PPS walk-up by stock market crooks, several I recognize.
I call these "low self-esteem" plays- manipulators,and those that embarrassingly ride their coattails,who have identified ways to jigger things for ill gained profits. Done by those who lack good trading skills.
Just look at the chart- every one of these walk-ups sell off.
SEC should investigate this, INO and other low PPS bios in the hands of the manipulator gang thrown off ST.
You can have the last word as I don't wish to further converse with those trying to rationalize an obvious BS play.
Analyst Actions: Sysorex Global Holdings Initiated With Buy And $2.50 Price Target At B. Riley
BY Midnight Trader — 8:49 AM ET 10/05/2015
08:49 AM EDT, 10/05/2015 (MT Newswires) -- Sysorex Global Holdings ( SYRX ) shares were initiated by B. Riley with a buy rating and $2.50 price target.
I did. After being down thousands, now up $454. Went with it- got in the zone, didn't attempt to impose what I think it should be, or over think at all.
In Carolinas now, meandering north. Lovely temps following muggy My-ami.
Ok, shortexpert, I'm willing to say there is more to this than I originally suspected.
Your posts have been informative.
Blah, blah, blah- no unattributed, factually inaccurate, obtuse posts can obscure from the knowing that PCAB is a pig in lipstick and high heels.
You're banking but will still be a #$%$ when you look in the mirror tomorrow.
LOL! A Market Cap of 1.6B for a company with a niche product selling 10-15 machines a year.
That's the last installment from Roche- then it's dilution as PACB has chronic negative cash flow.
The only question is when is this walk-up going to dump.